Feil Family Brain & Mind Research Institute

You are here

Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.

TitleInduction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Publication TypeJournal Article
Year of Publication2018
AuthorsKocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS
JournalJ Neurol
Volume265
Issue5
Pagination1226-1229
Date Published2018 May
ISSN1432-1459
KeywordsAdult, Alemtuzumab, Disability Evaluation, Disease Progression, Female, Follow-Up Studies, Humans, Immunologic Factors, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting, Remission Induction, Retrospective Studies, Treatment Outcome
Abstract

OBJECTIVE: To investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis.

METHODS: We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis.

RESULTS: In the 2 years prior to first dose of alemtuzumab, 82.8% of the 29 patients had a new lesion on MRI and/or a clinical relapse, with an ARR of 0.67. In the mean 24.7 month follow-up after the first dose of alemtuzumab, 17.2% of patients displayed new disease activity and the ARR was 0.08. 4 out of 5 patients who relapsed did so within 12 month post-first infusion and received a second dose. Of the 24 patients who did not relapse, 8 received a second dose at 1 year and 16 did not. 5 out of all 29 patients developed thyroid disorder.

CONCLUSIONS: Given that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen.

DOI10.1007/s00415-018-8845-4
Alternate JournalJ. Neurol.
PubMed ID29666985